Molecular basis of β thalassemia and potential therapeutic targets
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The remarkable phenotypic diversity of β thalassemia that range from severe anemia and transfusion-dependency, to a clinically asymptomatic state exemplifies how a spectrum of disease severity can be generated in single gene disorders. While the genetic basis for β thalassemia, and how severity of the anemia could be modified at different levels of its pathophysiology have been well documented, therapy remains largely supportive with bone marrow transplant being the only cure. Identification of the genetic variants modifying fetal hemoglobin (HbF) production in combination with α globin genotype provide some prediction of disease severity for β thalassemia but generation of a personalized genetic risk score to inform prognosis and guide management requires a larger panel of genetic modifiers yet to be discovered. Nonetheless, genetic studies have been successful in characterizing the key variants and pathways involved in HbF regulation, providing new therapeutic targets for HbF reactivation. BCL11A has been established as a quantitative repressor, and progress has been made in manipulating its expression using genomic and gene-editing approaches for therapeutic benefits. Recent discoveries and understanding in the mechanisms associated with ineffective and abnormal erythropoiesis have also provided additional therapeutic targets, a couple of which are currently being tested in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736 · cited 1×
“Several genes involved in iron homeostasis have now been characterized, including those encoding HFE (HFE), transferrin receptor 2 (TfR2), ferroportin (FPN), hepcidin (HAMP) and hemojuvelin (HJV) [78].”
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Genetic Mapping in Human Disease
Altshuler, D., Daly, M. J., & Lander, E. S. (2008) · Science · doi:10.1126/science.1156409 · Cited by 1,452 · cited 1×
“of the whole human genome and, by design, are more likely to reveal unsuspected interactions [62].”
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 3×
“The most advanced of these is the antisickling β-globin vector containing the HbAT87Q mutation (Bluebird Bio), first tested in a patient with transfusion-dependent HbE/β-thalassemia [144,145].”
Pathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154 · cited 1×
“β thalassemia is caused by a spectrum of mutations that results in a quantitative reduction of β globin chains that are structurally normal [3], in contrast to SCD which is caused by an abnormal Hb variant (HbS, βGlu6Val) that results from a point mutation in the HBB gene [4,5].”
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886 · cited 2×
“Dissection of the erythroid-specific enhancer down to a small region in the gene offers the possibility of disrupting this region and specifically targeting erythroid function using genome-editing technology such as zinc finger nucleases or CRISPR-Cas 9 [91,141].”
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)
Finberg, K. E., Heeney, M. M., Campagna, D. R., Aydınok, Y., Pearson, H. A., Hartman, K. R., Mayo, M. M., Samuel, S. M., Strouse, J. J., Markianos, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.130 · Cited by 675
Uda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V. G., Chen, W., Usala, G., Busonero, F., Maschio, A., Albai, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711566105 · Cited by 672
Long-range chromatin regulatory interactions in vivo
Carter, D., Chakalova, L., Osborne, C. S., Dai, Y.-F., & Fraser, P. (2002) · Nature Genetics · doi:10.1038/ng1051 · Cited by 663
Regulation of cytoplasmic mRNA decay
Schoenberg, D. R., & Maquat, L. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3160 · Cited by 656 · cited 1×
“control of the processed mRNA, mRNA harboring a PTC are destroyed and not transported to the cytoplasm in a phenomenon called (nonsense mediated RNA decay or NMD) to prevent the accumulation of mutant mRNAs coding for truncated peptides [39,40].”
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653 · cited 1×
“Fine-mapping demonstrated that these HbF-associated variants, such as rs1427407 in BCL11A, and rs9399137 in HMIP, are localized to enhancers that are erythroid-specific [89,90]}.”
Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Williams, T. N., Weatherall, D. J., & Hay, S. I. (2010) · Nature Communications · doi:10.1038/ncomms1104 · Cited by 629 · cited 1×
“Because carriers for α-thalassemia and HbS are similarly protected from the severe effects of falciparum malaria [7,8], regions where β-thalassemia is prevalent overlaps substantially with those of α-thalassemia and HbS.”
A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15
Menzel, S., Garner, C., Gut, I., Matsuda, F., Yamaguchi, M., Heath, S., Foglio, M., Zelenika, D., Boland, A., Rooks, H., et al. (2007) · Nature Genetics · doi:10.1038/ng2108 · Cited by 529
Self-citationLi, Q., Peterson, K. R., Fang, X., & Stamatoyannopoulos, G. (2002) · Blood · doi:10.1182/blood-2002-04-1104 · Cited by 456
Reactivation of developmentally silenced globin genes by forced chromatin looping
Deng, W., Rupon, J. W., Krivega, I., Breda, L., Motta, I., Jahn, K. S., Reik, A., Gregory, P. D., Rivella, S., Dean, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.050 · Cited by 443 · cited 1×
“One could also “de-repress” gamma-globin expression by forcing interaction of the β-locus control region (β-LCR) with the γ-gene using a synthetic DNA-binding protein [142,143].”
Nonsense-mediated mRNA decay in humans at a glance
Kurosaki, T., & Maquat, L. E. (2016) · Journal of Cell Science · doi:10.1242/jcs.181008 · Cited by 396 · cited 1×
“control of the processed mRNA, mRNA harboring a PTC are destroyed and not transported to the cytoplasm in a phenomenon called (nonsense mediated RNA decay or NMD) to prevent the accumulation of mutant mRNAs coding for truncated peptides [39,40].”
Control of globin gene expression during development and erythroid differentiation
Stamatoyannopoulos, G. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.007 · Cited by 393
Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin
Masuda, T., Wang, X., Maeda, M., Canver, M. C., Sher, F., Funnell, A. P. W., Fisher, C., Suciu, M., Martyn, G. E., Norton, L. J., et al. (2016) · Science · doi:10.1126/science.aad3312 · Cited by 373 · cited 2×
“In double knockout cells, HbF comprised> 90% of total hemoglobin suggesting that the silencing pathway of LRF is independent of BCL11A [131].”
KLF1 regulates BCL11A expression and γ- to β-globin gene switching
Zhou, D., Liu, K., Sun, C.-W., Pawlik, K. M., & Townes, T. M. (2010) · Nature Genetics · doi:10.1038/ng.637 · Cited by 367
Xu, J., Sankaran, V. G., Ni, M., Menne, T. F., Puram, R. V., Kim, W., & Orkin, S. H. (2010) · Genes & Development · doi:10.1101/gad.1897310 · Cited by 361 · cited 1×
“Functional studies in primary human erythroid progenitors and transgenic mice demonstrated that BCL11A represses γ globin and the silencing effect involves re-configuration of the HBB locus through interaction with GATA-1 and SOX6 that binds the proximal γ globin promoters [93,94].”
Abnormal RNA processing due to the exon mutation of βE-globin gene
Orkin, S. H., Kazazian, H. H., Antonarakis, S. E., Ostrer, H., Goff, S. C., & Sexton, J. P. (1982) · Nature · doi:10.1038/300768a0 · Cited by 298
Control of fetal hemoglobin: new insights emerging from genomics and clinical implications
Thein, S. L., Menzel, S., Lathrop, M., & Garner, C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp401 · Cited by 250
Self-citationPreza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57693 · Cited by 234 · cited 3×
“Several genes involved in iron homeostasis have now been characterized, including those encoding HFE (HFE), transferrin receptor 2 (TfR2), ferroportin (FPN), hepcidin (HAMP) and hemojuvelin (HJV) [78].”
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A
Xu, J., Bauer, D. E., Kerenyi, M. A., Vo, T. D., Hou, S., Hsu, Y.-J., Yao, H., Trowbridge, J. J., Mandel, G., & Orkin, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303976110 · Cited by 233 · cited 1×
“Functional studies in primary human erythroid progenitors and transgenic mice demonstrated that BCL11A represses γ globin and the silencing effect involves re-configuration of the HBB locus through interaction with GATA-1 and SOX6 that binds the proximal γ globin promoters [93,94].”
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Transferrin therapy ameliorates disease in β-thalassemic mice
Li, H., Rybicki, A. C., Suzuka, S. M., von Bonsdorff, L., Breuer, W., Hall, C. B., Cabantchik, Z. I., Bouhassira, E. E., Fabry, M. E., & Ginzburg, Y. Z. (2010) · Nature Medicine · doi:10.1038/nm.2073 · Cited by 192
Sedgewick, A. E., Timofeev, N., Sebastiani, P., So, J. C. C., Ma, E. S. K., Chan, L. C., Fucharoen, G., Fucharoen, S., Barbosa, C. G., Vardarajan, B. N., et al. (2008) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2008.06.007 · Cited by 172
Functional footprinting of regulatory DNA
Vierstra, J., Reik, A., Chang, K.-H., Stehling-Sun, S., Zhou, Y., Hinkley, S. J., Paschon, D. E., Zhang, L., Psatha, N., Bendana, Y. R., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3554 · Cited by 133 · cited 1×
“Dissection of the erythroid-specific enhancer down to a small region in the gene offers the possibility of disrupting this region and specifically targeting erythroid function using genome-editing technology such as zinc finger nucleases or CRISPR-Cas 9 [91,141].”
Chapter 4 β‐Globin Regulation and Long‐Range Interactions
Palstra, R., de Laat, W., & Grosveld, F. (2008) · Advances in genetics · doi:10.1016/s0065-2660(07)00004-1 · Cited by 131
Pathophysiology of β Thalassemia—A Guide to Molecular Therapies
Thein, S. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.31 · Cited by 103 · cited 5×
“Increased α globin production through co-inheritance of extra α globin genes (triplicated – ααα/αα or ααα/ααα, quadruplicated – αααα/αα, or duplication of the whole α globin gene cluster – αα/αα/αα) with heterozygous β thalassemia tips the globin chain imbalance further, converting a typically clinically asymptomatic…”
InfluentialSelf-citationMolecular therapies in β‐thalassaemia
Quek, L., & Thein, S. L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06408.x · Cited by 88
Self-citationBreda, L., Motta, I., Lourenco, S., Gemmo, C., Deng, W., Rupon, J. W., Abdulmalik, O. Y., Manwani, D., Blobel, G. A., & Rivella, S. (2016) · Blood · doi:10.1182/blood-2016-01-691089 · Cited by 83
Schmidt, P. J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J. S., & Fleming, M. D. (2015) · American Journal of Hematology · doi:10.1002/ajh.23934 · Cited by 77 · cited 1×
“An alternative method of increasing hepcidin in vivo is inhibition of the transmembrane serine protease TMPRSS6 which is essential in the activation of hepcidin [150].”
Jawaid, K., Wahlberg, K., Thein, S. L., & Best, S. (2010) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.05.006 · Cited by 64
Self-citation
Cited by
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype
Daniels, D. E., Ferrer-Vicens, I., Hawksworth, J., Andrienko, T. N., Finnie, E. M., Bretherton, N. S., Ferguson, D. C. J., Oliveira, A. S. F., Szeto, J.-Y. A., Wilson, M. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41961-9 · Cited by 8
Metadata
- Authors
- Thein, S. L.
- Venue
- Blood Cells, Molecules, and Diseases
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 70
- Pages
- 54-65
- ISSN
- 1079-9796 (ISSN-L)
- OpenAlex
- W2654493239
- Cited by
- 209
- References
- 36
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.